Literature DB >> 26618824

Vaccine strategies against cystic fibrosis pathogens.

Vincent Le Moigne1, Jean-Louis Gaillard1,2, Jean-Louis Herrmann1,2.   

Abstract

A great number of cystic fibrosis (CF) pathogens such as Pseudomonas aeruginosa, the Burkholderia cepacia and the Mycobacterium abscessus complex raised difficult therapeutic problems due to their intrinsic multi-resistance to numerous antibiotics. Vaccine strategies represent one of the key weapons against these multi-resistant bacteria in a number of clinical settings like CF. Different strategies are considered in order to develop such vaccines, linked either to priming the host response, or by exploiting genomic data derived from the bacterium. Interestingly, virulence factors synthesized by various pathogens might serve as targets for vaccine development and have been, for example, evaluated in the context of CF.

Entities:  

Keywords:  Burkholderia spp.; Mycobacterium abscessus; Pseudomonas aeruginosa; cystic fibrosis; vaccine

Mesh:

Substances:

Year:  2016        PMID: 26618824      PMCID: PMC4964708          DOI: 10.1080/21645515.2015.1102810

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  71 in total

1.  Cystic fibrosis complicated by multiresistant tuberculosis.

Authors:  Irina K Asherova; Jean Feigelson; Ludmila A Vasilyeva; Valery J Gabitov
Journal:  Acta Paediatr       Date:  2006-11       Impact factor: 2.299

Review 2.  Optimizing vaccine development.

Authors:  Daniel F Hoft; Vladimir Brusic; Isaac G Sakala
Journal:  Cell Microbiol       Date:  2011-06-02       Impact factor: 3.715

3.  Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers.

Authors:  Dirk Bumann; Christoph Behre; Katharina Behre; Steffen Herz; Britta Gewecke; J Engelbert Gessner; Bernd Ulrich von Specht; Ulrich Baumann
Journal:  Vaccine       Date:  2009-11-01       Impact factor: 3.641

4.  Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient.

Authors:  Jennifer L Taylor; Scott M Palmer
Journal:  J Heart Lung Transplant       Date:  2006-07-11       Impact factor: 10.247

Review 5.  New perspectives in the management of Pseudomonas aeruginosa infections.

Authors:  Dianella Savoia
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

6.  Protection against virulent Mycobacterium avium infection following DNA vaccination with the 35-kilodalton antigen is accompanied by induction of gamma interferon-secreting CD4(+) T cells.

Authors:  E Martin; A T Kamath; J A Triccas; W J Britton
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

7.  Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.

Authors:  Scott D Sagel; Ronald L Gibson; Julia Emerson; Sharon McNamara; Jane L Burns; Jeffrey S Wagener; Bonnie W Ramsey
Journal:  J Pediatr       Date:  2008-09-25       Impact factor: 4.406

Review 8.  FDA guidance on prophylactic DNA vaccines: analysis and recommendations.

Authors:  Dennis M Klinman; Sven Klaschik; Debra Tross; Hidekazu Shirota; Folkert Steinhagen
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

9.  A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.

Authors:  Eric T Weimer; Haiping Lu; Nancy D Kock; Daniel J Wozniak; Steven B Mizel
Journal:  Infect Immun       Date:  2009-04-06       Impact factor: 3.441

10.  Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations.

Authors:  Emilie Catherinot; Anne-Laure Roux; Marie-Anne Vibet; Gil Bellis; Sophie Ravilly; Lydie Lemonnier; Evelyne Le Roux; Claire Bernède-Bauduin; Muriel Le Bourgeois; Jean-Louis Herrmann; Didier Guillemot; Jean-Louis Gaillard
Journal:  J Cyst Fibros       Date:  2012-07-31       Impact factor: 5.482

View more
  3 in total

1.  MgtC as a Host-Induced Factor and Vaccine Candidate against Mycobacterium abscessus Infection.

Authors:  Vincent Le Moigne; Claudine Belon; Céline Goulard; Geoffrey Accard; Audrey Bernut; Bruno Pitard; Jean-Louis Gaillard; Laurent Kremer; Jean-Louis Herrmann; Anne-Béatrice Blanc-Potard
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

Review 2.  The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases.

Authors:  Susan L Baldwin; Sasha E Larsen; Diane Ordway; Gail Cassell; Rhea N Coler
Journal:  PLoS Negl Trop Dis       Date:  2019-02-14

Review 3.  Yeasts in nanotechnology-enabled oral vaccine and gene delivery.

Authors:  Elena Ivanova
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.